Foundry Partners LLC Sells 26,560 Shares of Accuray Incorporated (NASDAQ:ARAY)

Foundry Partners LLC trimmed its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 1.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,470,055 shares of the medical equipment provider’s stock after selling 26,560 shares during the period. Foundry Partners LLC’s holdings in Accuray were worth $4,160,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Heartland Advisors Inc. lifted its stake in shares of Accuray by 6.8% in the 3rd quarter. Heartland Advisors Inc. now owns 2,847,800 shares of the medical equipment provider’s stock valued at $7,746,000 after acquiring an additional 181,050 shares during the last quarter. North Star Investment Management Corp. increased its stake in Accuray by 16.8% in the 4th quarter. North Star Investment Management Corp. now owns 1,095,920 shares of the medical equipment provider’s stock worth $3,101,000 after purchasing an additional 157,975 shares during the period. Kennedy Capital Management LLC lifted its position in Accuray by 8.8% in the third quarter. Kennedy Capital Management LLC now owns 995,536 shares of the medical equipment provider’s stock valued at $2,708,000 after purchasing an additional 80,455 shares during the last quarter. First Eagle Investment Management LLC lifted its position in Accuray by 44.3% in the third quarter. First Eagle Investment Management LLC now owns 910,925 shares of the medical equipment provider’s stock valued at $2,478,000 after purchasing an additional 279,478 shares during the last quarter. Finally, Silverberg Bernstein Capital Management LLC purchased a new stake in shares of Accuray during the fourth quarter valued at approximately $1,194,000. 64.08% of the stock is owned by institutional investors.

Accuray Trading Down 0.5 %

Shares of NASDAQ ARAY traded down $0.01 during midday trading on Monday, hitting $2.13. 88,854 shares of the company traded hands, compared to its average volume of 437,319. Accuray Incorporated has a 12-month low of $2.10 and a 12-month high of $4.30. The firm has a market cap of $211.23 million, a P/E ratio of -14.27 and a beta of 1.44. The stock has a 50-day moving average price of $2.55 and a 200 day moving average price of $2.67. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.84 and a current ratio of 1.58.

Accuray (NASDAQ:ARAY) last posted its earnings results on Wednesday, January 31st. The medical equipment provider reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). The firm had revenue of $107.24 million for the quarter, compared to analysts’ expectations of $107.11 million. Accuray had a negative return on equity of 28.11% and a negative net margin of 3.25%. During the same quarter last year, the company posted ($0.02) EPS. As a group, analysts expect that Accuray Incorporated will post -0.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ARAY shares. Roth Mkm began coverage on shares of Accuray in a report on Tuesday, February 13th. They set a “buy” rating and a $9.00 price target for the company. Roth Capital restated a “buy” rating on shares of Accuray in a research report on Tuesday, February 13th. Finally, TheStreet lowered Accuray from a “c-” rating to a “d+” rating in a research report on Wednesday, February 14th. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.25.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.